An NDM-1 carbapenemase-producing Escherichia coli isolate of sequence type 131 (ST131) that belonged to phylogenetic group B2 was obtained from a patient with a urinary tract infection who returned to the United States after a recent hospitalization while visiting India. NDM-1-producing E. coli ST131 had significantly more virulence factors than NDM-1-producing E. coli ST101, previously isolated from a patient in Canada. The presence of NDM ␤-lactamases in a very successful and virulent E. coli sequence type is of concern.
The development of resistance to the carbapenems in the Enterobacteriaceae is a major issue, since these agents are often the last line of effective therapy available for the treatment of infections caused by these bacteria (13) . There are 3 types of ␤-lactamases that inactivate the carbapenems (also called carbapenemases): the KPC types, the metallo-␤-lactamases (MBLs), and the oxacillinases (13) . The 2 most common types of MBL found in Enterobacteriaceae are the VIM and IMP types (7) .
Recently, a new type of MBL, named NDM-1, has been described in bacteria (Klebsiella pneumoniae and Escherichia coli) recovered from a Swedish patient who was hospitalized in New Delhi, India (24) . Kumarasamy and colleagues (11) provided evidence that NDM-producing Enterobacteriaceae (mostly K. pneumoniae and E. coli) are widespread in India, Pakistan, and the United Kingdom. NDM-producing Enterobacteriaceae have also recently been isolated from patients residing in the United States (1), the Netherlands (12), Australia (20) , Canada (15) , France (19) , and the Sultanate of Oman (18) . Most of the patients received medical care while visiting the subcontinent of Pakistan, India, and Bangladesh.
(Part of this work was presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 13 September 2010.)
A study was designed to characterize two carbapenem-resistant E. coli isolates, from Chicago, IL, and Alberta, Canada (14) , obtained from patients with recent hospitalization while visiting India. Since very little information about the virulence factors (VFs) associated with E. coli that produces NDM-1 is available, we investigated the phylogenetic groups and virulence traits of these isolates.
Antimicrobial susceptibility was determined with a Microscan NEG MIC 30 panel (Siemens, Burlington, ON, Canada). The MICs of the following drugs were determined: amoxicillin-clavulanic acid (AMC), piperacillin-tazobactam (TZP), cefoxitin (FOX), ceftriaxone (CRO), ceftazidime (CAZ), aztreonam (ATM), meropenem (MER), ertapenem (ERT), amikacin (AMK), gentamicin (GEN), tobramycin (TOB), ciprofloxacin (CIP), nitrofurantoin (NIT), and trimethoprim-sulfamethoxazole (SXT). Additional susceptibilities for imipenem (IPM), MER, ERT, tigecycline (TIG), and colistin (CST) were performed using Etest methodology per the manufacturer's instructions (AB BioDisk, Solna, Sweden). Throughout this study, results were interpreted using CLSI criteria for broth dilution (6) . Fosfomycin (FOF) susceptibility was determined using the CLSI disk methodology (6) .
The presence of MBLs in E. coli was determined with an MBL Etest (AB BioDisk, Solna, Sweden). Isoelectric focusing (IEF) was performed as previously described (16) . PCR amplification and sequencing of bla VIM , bla IMP , bla NDM , bla CTX-M , bla OXA , bla TEM , and bla SHV were carried out as previously described (14, 16) . Amplification of the qnrA, qnrS, and qnrB genes was undertaken with a multiplex PCR (22) , while aac(6Ј)-Ib and qepA were amplified as previously described (21, 23) . Multilocus sequence typing (MLST) was performed using seven conserved housekeeping genes (adk, fumC, gyrB, icd, mdh, purA, and recA) (http://mlst.ucc.ie/mlst/dbs /Ecoli). Serotype O25 was confirmed using a PCR for the pabB allele (5). The E. coli isolates were assigned to one of the four main E. coli phylogenetic groups by the use of a multiplex PCR-based method (4). VFs for extraintestinal pathogenic E. coli (ExPEC)-associated genes were determined by established PCR-based assays (17) . Plasmid sizes were determined as previously described (2), and plasmids were assigned to families by PCR-based replicon typing (3). A conjugation experiment was performed by mating-out assays with nutrient agar containing IPM, 2 g/ml, and with E. coli J53 (azide concentration of 100 g/ml) as the recipient.
The patient was a 40-year-old male paraplegic who traveled to New Delhi, India, for a surgical procedure in 2010. Three to 4 months after his return to the United States, he presented to an emergency department at a hospital in the Chicago metropolitan area with nausea, vomiting, dysuria, and frequent urination. The diagnosis of urinary tract infection (UTI) was made, and the patient was admitted. Due to the history of sepsis with multiresistant E. coli, the patient was placed in isolation with contact precautions. A Foley catheter-collected urine culture yielded E. coli CH01 at Ͼ10 5 CFU per ml of urine. The patient was treated with oral nitrofurantoin at 100 mg twice a day for 7 days. His urinary tract infection improved clinically, and a follow-up urine culture taken 2 days after the completion of the nitrofurantoin treatment showed no growth. He was discharged after 7 days. Active surveillance was performed with rectal swabs in patients from the same ward and failed to identify additional cases.
The characteristics of E. coli CH01 (from Chicago) and E. coli MH01 (from Canada) are shown in Table 1 , as are the MICs obtained with the Microscan NEG MIC 30 panels. Additional MICs were as follows; MER, 16 g/ml; IPM, 16 g/ml; ERT, Ͼ32 g/ml; TIG, 0.25 g/ml; and CST, 0.125 g/ml. The zone size for FOF was 27 mm for CH01. CH01 was susceptible only to NIT, TIG, and FOF, while the CST MIC was 0.125 g/ml. The transconjugant obtained with CH01 (i.e., CH01A) showed an MBL phenotype; plasmid analysis showed that CH01A harbored the 120-kb plasmid with markers for kanamycin, gentamicin, tobramycin, and trimethoprim-sulfamethoxazole. PCR confirmed that CH01A contained bla NDM ; CH01A belonged to the IncFIA replicon group. CH01 belonged to phylogenetic group B2 and sequence type 131 (ST131) and showed a virulence profile identical to those of a different ST131 strain isolated in Calgary, Alberta, Canada, during 2007 that produced CTX-M-15, OXA-1, and TEM-1 (data not shown). CH01 had significantly more virulence factors than MH01, previously isolated from a patient in Canada (Table 1) .
ST131 is a very successful clone among CTX-M-producing and fluoroquinolone-resistant E. coli isolates (9) . A study from Johnson and colleagues showed that that ST131 isolates have a fitness advantage because of their group B2 genomic backbone (8) and appear to combine resistance and virulence, which traditionally have been mutually exclusive in E. coli (10) . E. coli ST131 that produces NDM-1 had previously been described from a patient that recently returned to France after living in India for several years (19) .
The recent pandemic caused by E. coli ST131 with CTX-M ␤-lactamases, which began in 2003, highlights the ability of a successful clone to spread rapidly, and it is possible that E. coli ST131 isolates that produce NDM-1 could also cause a similar pandemic. If this emerging public health threat is ignored, it is possible that in the near future, the medical community will be confronted with carbapenem-resistant E. coli that causes common infections, such as UTIs. The identification of ST131 isolates that produce NDM-1 has grave implications for the future treatment of community-associated infections. The widespread and successful dissemination of ST131 and its distinctive combination of resistance and virulence need urgent investigation.
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